Ironwood cuts 120 jobs (50% of workforce) amid apraglutide submission, Shionogi's RSV drug succeeds in Phase 2, and multiple companies announce deals and layoffs.

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

Af­ter see­ing its Covid-19 drug fail in a Phase 3 tri­al last year, Sh­iono­gi on Thurs­day won a $375 mil­lion award from HHS to de­vel­op … ...

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced ...

Respiratory syncytial virus (RSV) causes cold-like symptoms in most people but can cause more serious problems in some, especially babies and older adults. Almost all children get RSV at least once by ...

Winter also marks the height of the respiratory virus season, a period of sniffles, sneezes, congestion, fever and other maladies brought about primarily by four pathogens: the respiratory syncytial ...

Nearly 80% of infants born during the late 2023 and early 2024 respiratory syncytial virus (RSV) season received protection against the virus, according to a recent study published in JAMA Network.

Cases of RSV across the country are considered "very high," as rates of other acute respiratory illnesses are also high, the CDC reported Monday. Here's what to know about RSV. Iowa currently is ...

The company’s strategy moving forward will centre on driving sales from its currently marketed products; its Covid-19 vaccine Spikevax, approved by the US Food and Drug Administration (FDA) in January ...

As you dive into your New Year’s resolutions, taking precautions to protect yourself from a quartet of infectious diseases can lessen your odds of starting off 2025 sick.